Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9378893 | 0.90 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9381492 | 0.88 | CYP1A2 (0.57) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9377162 | 0.86 | CYP1A2 (0.61) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9378899 | 0.84 | CYP1A2 (0.58) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9382613 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9377996 | 0.80 | CYP1A2 (0.63) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9378050 | 0.79 | CYP1A2 (0.52) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9378601 | 0.79 | CYP1A2 (0.57) | CYP1A2ACHE | |
| SCHEMBL3807927 | 0.78 | CYP1A2 (0.72) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL194467 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0368188-B1 | 1,2,3,4-Tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-09-21 | — | — | EP | claimed |
| EP-0368188-A1 | 1,2,3,4-Tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-16 | — | — | EP | claimed |
| JP-3153667-A | — | — | None | — | — | JP | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0368188-B1 | 1,2,3,4-Tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-09-21 | — | — | EP | disclosed |
| JP-H03153667-A | 1,2,3,4-TETRAHYDRO-1,9-ACRIDINEDIAMINES | HOECHST ROUSSEL PHARMACEUT INC | 1991-07-01 | — | — | JP | disclosed |
| EP-0368188-A1 | 1,2,3,4-Tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | CYP1A2 725/4885CYP2C9 1396/4885TSHR 3362/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CYP1A2 1169/4885CYP2C9 587/4885TSHR 4261/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | CYP1A2 1433/4885CYP2C9 710/4885TSHR 4603/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CYP1A2 1276/4885CYP2C9 616/4885TSHR 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.